Klodeta Kura, Philip Milton, Jonathan I D Hamley, Martin Walker, Didier K Bakajika, Eric M Kanza, Nicholas O Opoku, Hayford Howard, Maurice M Nigo, Sampson Asare, George Olipoh, Simon K Attah, Germain L Mambandu, Kambale Kasonia Kennedy, Kambale Kataliko, Mupenzi Mumbere, Christine M Halleux, Adrian Hopkins, Annette C Kuesel, Sally Kinrade, Maria-Gloria Basáñez
Epidemiological and modelling studies suggest that elimination of Onchocerca volvulus transmission (EoT) throughout Africa may not be achievable with annual mass drug administration (MDA) of ivermectin alone, particularly in areas of high endemicity and vector density. Single-dose Phase II and III clinical trials demonstrated moxidectin's superiority over ivermectin for prolonged clearance of O. volvulus microfilariae. We used the stochastic, individual-based EPIONCHO-IBM model to compare the probabilities of reaching EoT between ivermectin and moxidectin MDA for a range of endemicity levels (30 to 70% baseline microfilarial prevalence), treatment frequencies (annual and biannual) and therapeutic coverage/adherence values (65 and 80% of total population, with, respectively, 5 and 1% of systematic non-adherence)...
October 9, 2023: Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences